三元生物：公司第三季度销售收入同比增长，海外收入占比较上半年略有下降

Core Viewpoint - The announcement from Sanwei Biological highlights the significant impact of the U.S. Department of Commerce's preliminary ruling on the anti-dumping investigation of erythritol, which imposes a preliminary tax rate of 450.64% on the company, creating barriers for exports to the U.S. market [2] Group 1 - On July 15, 2025, the U.S. Department of Commerce announced the preliminary ruling in the anti-dumping investigation, listing the company as a mandatory respondent [2] - The final ruling, originally scheduled for December 1, 2025, is expected to be delayed due to the recent U.S. government shutdown [2] - The preliminary ruling has created a significant obstacle for Chinese erythritol exports to the U.S., leading to a temporary tightening of supply in the U.S. market [2] Group 2 - Despite the challenges in the U.S. market, demand in North America remains, and imports of the company's products from neighboring countries like Canada and Mexico have gradually increased [2] - The company's third-quarter sales revenue showed a year-on-year increase, although the proportion of overseas revenue slightly decreased compared to the first half of the year [2] - Export growth to other countries and regions has partially offset the decline in the U.S. market [2]